Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10989857 | 0.89 | LMNA (0.57) | LMNAL3MBTL1KMT2AMEN1POLB | |
| SCHEMBL3923738 | 0.82 | LMNA (0.62) | LMNAKMT2AMEN1POLBKDM4E | |
| SCHEMBL4715262 | 0.81 | ALDH1A1 (0.50) | LMNASMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL10989860 | 0.80 | LMNA (0.56) | LMNAKMT2AMEN1CA12CA9 | |
| SCHEMBL13543492 | 0.77 | LMNA (0.59) | LMNAKMT2AMEN1CA12CA2 | |
| SCHEMBL3922786 | 0.76 | LMNA (0.62) | LMNAKMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL10989432 | 0.76 | ATM (0.67) | LMNAKMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL4175111 | 0.74 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1POLBCA12CA2 | |
| SCHEMBL3920308 | 0.74 | LMNA (0.68) | LMNASMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL9462804 | 0.74 | SMN1; SMN2 (0.81) | SMN1; SMN2KMT2AMEN1POLBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | LMNA 4722/4885SMN1; SMN2 2089/4885L3MBTL1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.